Oncogenic PI3K deregulates transcription and translation (original) (raw)

• Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004). The first study to describe point mutations in the gene that encodes p110α in various solid tumours.
  Article CAS PubMed Google Scholar
• Bachman, K. E. et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3, 772–775 (2004).
  Article CAS PubMed Google Scholar
• Campbell, I. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678–7681 (2004).
  Article CAS PubMed Google Scholar
• Broderick, D. K. et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64, 5048–5050 (2004).
  Article CAS PubMed Google Scholar
• Lee, J. W. et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24, 1477–1480 (2005).
  Article CAS PubMed Google Scholar
• Levine, D. A. et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11, 2875–2878 (2005).
  Article CAS PubMed Google Scholar
• Li, V. S. et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 5, 29 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Saal, L. H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554–2559 (2005).
  Article CAS PubMed Google Scholar
• Wang, Y., Helland, A., Holm, R., Kristensen, G. B. & Borresen-Dale, A. L. PIK3CA mutations in advanced ovarian carcinomas. Hum. Mutat. 25, 322 (2005).
  Article CAS PubMed Google Scholar
• Hartmann, C., Bartels, G., Gehlhaar, C., Holtkamp, N. & von Deimling, A. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol. 109, 639–642 (2005).
  Article CAS PubMed Google Scholar
• Vanhaesebroeck, B. & Waterfield, M. D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253, 239–254 (1999).
  Article CAS PubMed Google Scholar
• Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).
  Article CAS PubMed Google Scholar
• Okkenhaug, K. & Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nature Rev. Immunol. 3, 317–330 (2003).
  Article CAS Google Scholar
• Wymann, M. P., Zvelebil, M. & Laffargue, M. Phosphoinositide 3-kinase signalling — which way to target? Trends Pharmacol. Sci. 24, 366–376 (2003).
  Article CAS PubMed Google Scholar
• Deane, J. A. & Fruman, D. A. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 22, 563–598 (2004).
  Article CAS PubMed Google Scholar
• Okkenhaug, K. & Vanhaesebroeck, B. New responsibilities for the PI3K regulatory subunit p85α. Sci. STKE 65, PE1 (2001).
  Google Scholar
• Rodriguez-Viciana, P. et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527–532 (1994).
  Article CAS PubMed Google Scholar
• Rodriguez-Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D. & Downward, J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 15, 2442–2451 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Corvera, S. & Czech, M. P. Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol. 8, 442–446 (1998).
  Article CAS PubMed Google Scholar
• Balendran, A. et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr. Biol. 9, 393–404 (1999).
  Article CAS PubMed Google Scholar
• Persad, S. et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J. Biol. Chem. 276, 27462–27469 (2001).
  Article CAS PubMed Google Scholar
• Toker, A. & Newton, A. C. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem. 275, 8271–8274 (2000).
  Article CAS PubMed Google Scholar
• Feng, J., Park, J., Cron, P., Hess, D. & Hemmings, B. A. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J. Biol. Chem. 279, 41189–41196 (2004).
  Article CAS PubMed Google Scholar
• Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex. Science 307, 1098–1101 (2005).
  Article CAS PubMed Google Scholar
• Wishart, M. J. & Dixon, J. E. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol. 12, 579–585 (2002).
  Article CAS PubMed Google Scholar
• Maehama, T., Taylor, G. S. & Dixon, J. E. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu. Rev. Biochem. 70, 247–279 (2001).
  Article CAS PubMed Google Scholar
• Ali, I. U., Schriml, L. M. & Dean, M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl Cancer Inst. 91, 1922–1932 (1999).
  Article CAS PubMed Google Scholar
• Eng, C. PTEN: one gene, many syndromes. Hum. Mutat. 22, 183–198 (2003).
  Article CAS PubMed Google Scholar
• Leslie, N. R. & Downes, C. P. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382, 1–11 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Simpson, L. & Parsons, R. PTEN: life as a tumor suppressor. Exp. Cell Res. 264, 29–41 (2001).
  Article CAS PubMed Google Scholar
• Staal, S. P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl Acad. Sci. USA 84, 5034–5037 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Chang, H. W. et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276, 1848–1850 (1997). Reports the isolation and identification of the v-P3k oncoprotein, a retroviral and tumorigenic homologue of p110α.
  Article CAS PubMed Google Scholar
• Bellacosa, A., Testa, J. R., Staal, S. P. & Tsichlis, P. N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254, 274–277 (1991).
  CAS PubMed Google Scholar
• Aoki, M. et al. The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J. Biol. Chem. 275, 6267–6275 (2000).
  Article CAS PubMed Google Scholar
• Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P. & Vogt, P. K. The akt kinase: molecular determinants of oncogenicity. Proc. Natl Acad. Sci. USA 95, 14950–14955 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Borlado, L. R. et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14, 895–903 (2000).
  Article CAS PubMed Google Scholar
• Janssen, J. W., Schleithoff, L., Bartram, C. R. & Schulz, A. S. An oncogenic fusion product of the phosphatidylinositol 3-kinase p85b subunit and HUMORF8, a putative deubiquitinating enzyme. Oncogene 16, 1767–1772 (1998).
  Article CAS PubMed Google Scholar
• Jimenez, C. et al. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J. 17, 743–753 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Jucker, M. et al. Expression of a mutated form of the p85α regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 16, 894–901 (2002).
  Article CAS PubMed Google Scholar
• Philp, A. J. et al. The phosphatidylinositol 3′-kinase p85α gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426–7429 (2001).
  CAS PubMed Google Scholar
• Katoh, M. Human FOX gene family (Review). Int. J. Oncol. 25, 1495–1500 (2004).
  CAS PubMed Google Scholar
• Vogt, P. K., Jiang, H. & Aoki, M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 4, 908–913 (2005).
  Article CAS PubMed Google Scholar
• Tran, H., Brunet, A., Griffith, E. C. & Greenberg, M. E. The many forks in FOXO's road. Sci. STKE 172, RE5 (2003).
  Google Scholar
• Medema, R. H., Kops, G. J., Bos, J. L. & Burgering, B. M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782–787 (2000).
  Article CAS PubMed Google Scholar
• Seoane, J., Le, H. V., Shen, L., Anderson, S. A. & Massague, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211–223 (2004). Shows that FOXO1 represses p21 cip1 gene expression in a complex with Smad. The oncoprotein Fox G1 binds to this complex and inhibits its repressive activity.
  Article CAS PubMed Google Scholar
• Schmidt, M. et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol. Cell. Biol. 22, 7842–7852 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ramaswamy, S., Nakamura, N., Sansal, I., Bergeron, L. & Sellers, W. R. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2, 81–91 (2002).
  Article CAS PubMed Google Scholar
• Biggs, W. H., Meisenhelder, J., Hunter, T., Cavenee, W. K. & Arden, K. C. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl Acad. Sci. USA 96, 7421–7426 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857–868 (1999).
  Article CAS PubMed Google Scholar
• Kops, G. J. et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398, 630–634 (1999).
  Article CAS PubMed Google Scholar
• Takaishi, H. et al. Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proc. Natl Acad. Sci. USA 96, 11836–11841 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Tang, E. D., Nunez, G., Barr, F. G. & Guan, K. L. Negative regulation of the forkhead transcription factor FKHR by Akt. J. Biol. Chem. 274, 16741–16746 (1999).
  Article CAS PubMed Google Scholar
• Brownawell, A. M., Kops, G. J., Macara, I. G. & Burgering, B. M. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol. Cell. Biol. 21, 3534–3546 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Brunet, A. et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J. Cell Biol. 156, 817–828 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Rena, G., Prescott, A. R., Guo, S., Cohen, P. & Unterman, T. G. Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochem. J. 354, 605–612 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, X. et al. Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. Biochem. J. 378, 839–849 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Obsil, T., Ghirlando, R., Anderson, D. E., Hickman, A. B. & Dyda, F. Two 14-3-3 binding motifs are required for stable association of Forkhead transcription factor FOXO4 with 14-3-3 proteins and inhibition of DNA binding. Biochemistry 42, 15264–15272 (2003).
  Article CAS PubMed Google Scholar
• Perrot, V. & Rechler, M. M. The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. Mol. Endocrinol. 19, 2283–2298 (2005).
  Article CAS PubMed Google Scholar
• Aoki, M., Jiang, H. & Vogt, P. K. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc. Natl Acad. Sci. USA 101, 13613–13617 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, H. et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl Acad. Sci. USA 102, 1649–1654 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Plas, D. R. & Thompson, C. B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 278, 12361–12366 (2003).
  Article CAS PubMed Google Scholar
• Matsuzaki, H., Daitoku, H., Hatta, M., Tanaka, K. & Fukamizu, A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc. Natl Acad. Sci. USA 100, 11285–11290 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Hu, M. C. et al. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225–237 (2004). Reports that IκB is the kinase responsible for inactivation of FOXO3a in cancer cells that lack elevated levels of phospho-AKT.
  Article CAS PubMed Google Scholar
• Aggarwal, B. B. Nuclear factor-κB: the enemy within. Cancer Cell 6, 203–208 (2004).
  Article CAS PubMed Google Scholar
• Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301–310 (2002).
  Article CAS Google Scholar
• Nakanishi, C. & Toi, M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nature Rev. Cancer 5, 297–309 (2005).
  Article CAS Google Scholar
• Ozes, O. N. et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82–85 (1999).
  Article CAS PubMed Google Scholar
• Romashkova, J. A. & Makarov, S. S. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401, 86–90 (1999).
  Article CAS PubMed Google Scholar
• Kane, L. P., Mollenauer, M. N., Xu, Z., Turck, C. W. & Weiss, A. Akt-dependent phosphorylation specifically regulates Cot induction of NF-κ B-dependent transcription. Mol. Cell. Biol. 22, 5962–5974 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Madrid, L. V., Mayo, M. W., Reuther, J. Y. & Baldwin, A. S. Jr. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-κ B through utilization of the Iκ B kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276, 18934–18940 (2001).
  Article CAS PubMed Google Scholar
• Sizemore, N., Leung, S. & Stark, G. R. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-κB p65/RelA subunit. Mol. Cell. Biol. 19, 4798–4805 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H. & Stark, G. R. Distinct roles of the Iκ B kinase α and β subunits in liberating nuclear factor κ B (NF-κ B) from Iκ B and in phosphorylating the p65 subunit of NF-κ B. J. Biol. Chem. 277, 3863–3869 (2002).
  Article CAS PubMed Google Scholar
• Asano, T. et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 23, 8571–8580 (2004).
  Article CAS PubMed Google Scholar
• Liptay, S. et al. Mitogenic and antiapoptotic role of constitutive NF-κB/Rel activity in pancreatic cancer. Int. J. Cancer 105, 735–746 (2003).
  Article CAS PubMed Google Scholar
• Kim, S. et al. Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-α/nuclear factor-κB (NF-κB)-inducing kinase/NF-κB pathway is linked to a default IκB-α autoregulatory loop. J. Biol. Chem. 279, 4285–4291 (2004).
  Article CAS PubMed Google Scholar
• Vasudevan, K. M., Gurumurthy, S. & Rangnekar, V. M. Suppression of PTEN expression by NF-κ B prevents apoptosis. Mol. Cell. Biol. 24, 1007–1021 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wanzel, M. et al. Akt and 14-3-3ε regulate Miz1 to control cell-cycle arrest after DNA damage. Nature Cell Biol. 7, 30–41 (2005).
  Article CAS PubMed Google Scholar
• Zhou, B. P. et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biol. 3, 973–982 (2001).
  Article CAS PubMed Google Scholar
• Mayo, L. D. & Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. USA 98, 11598–11603 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Boyle, W. J. et al. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64, 573–584 (1991).
  Article CAS PubMed Google Scholar
• de Groot, R. P., Auwerx, J., Bourouis, M. & Sassone-Corsi, P. Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy. Oncogene 8, 841–847 (1993).
  CAS PubMed Google Scholar
• Nikolakaki, E., Coffer, P. J., Hemelsoet, R., Woodgett, J. R. & Defize, L. H. Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. Oncogene 8, 833–840 (1993).
  CAS PubMed Google Scholar
• Gregory, M. A., Qi, Y. & Hann, S. R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 278, 51606–51612 (2003).
  Article CAS PubMed Google Scholar
• Sears, R. et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501–2514 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Rubinfeld, B. et al. Binding of GSK3β to the APC–β-catenin complex and regulation of complex assembly. Science 272, 1023–1026 (1996).
  Article CAS PubMed Google Scholar
• Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785–789 (1995).
  Article CAS PubMed Google Scholar
• Wei, W., Jin, J., Schlisio, S., Harper, J. W. & Kaelin, W. G. Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25–33 (2005). Shows that GSK3 mediated phosphorylation marks c-Jun for proteasomal degradation, a mechanism that is no longer in place for oncogenic v-Jun.
  Article CAS PubMed Google Scholar
• Jiang, B. H. et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12, 363–369 (2001).
  CAS PubMed Google Scholar
• Hamilton, G. S. & Steiner, J. P. Immunophilins: beyond immunosuppression. J. Med. Chem. 41, 5119–5143 (1998).
  Article CAS PubMed Google Scholar
• Vezina, C., Kudelski, A. & Sehgal, S. N. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28, 721–726 (1975).
  Article CAS Google Scholar
• Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78, 35–43 (1994).
  Article CAS PubMed Google Scholar
• Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756–758 (1994).
  Article CAS PubMed Google Scholar
• Chiu, M. I., Katz, H. & Berlin, V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl Acad. Sci. USA 91, 12574–12578 (1994). References 91–93 identify mammalian TOR as a target of the FKBP12–rapamycin complex.
  Article CAS PubMed PubMed Central Google Scholar
• Chen, J., Zheng, X. F., Brown, E. J. & Schreiber, S. L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl Acad. Sci. USA 92, 4947–4951 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Choi, J., Chen, J., Schreiber, S. L. & Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239–242 (1996).
  Article CAS PubMed Google Scholar
• Oshiro, N. et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9, 359–366 (2004).
  Article CAS PubMed Google Scholar
• Thomas, G., Sabatini, D. M. & Hall, N. M. (Eds.) TOR — Target of Rapamycin (Springer-Verlag, Berlin, 2004). A comprehensive compilation of literature on TOR.
  Book Google Scholar
• Mayer, C., Zhao, J., Yuan, X. & Grummt, I. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev. 18, 423–434 (2004). Shows that TOR regulates Pol I activity through reciprocal phosphorylation of TIF-IA.
  Article CAS PubMed PubMed Central Google Scholar
• Martin, D. E., Soulard, A. & Hall, M. N. TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1. Cell 119, 969–979 (2004).
  Article CAS PubMed Google Scholar
• Hannan, K. M. et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 23, 8862–8877 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Mahajan, P. B. Modulation of transcription of rRNA genes by rapamycin. Int. J. Immunopharmacol. 16, 711–721 (1994).
  Article CAS PubMed Google Scholar
• Zaragoza, D., Ghavidel, A., Heitman, J. & Schultz, M. C. Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway. Mol. Cell. Biol. 18, 4463–4470 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926–1945 (2004). An excellent review of the signalling network that surrounds TOR.
  Article CAS PubMed Google Scholar
• Montagne, J. et al. Drosophila S6 kinase: a regulator of cell size. Science 285, 2126–2129 (1999).
  Article CAS PubMed Google Scholar
• Radimerski, T. et al. dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nature Cell Biol. 4, 251–255 (2002).
  Article CAS PubMed Google Scholar
• Fingar, D. C., Salama, S., Tsou, C., Harlow, E. & Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16, 1472–1487 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Pende, M. et al. S6K1−/−/S6K2−/− mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24, 3112–3124 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Jefferies, H. B. et al. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16, 3693–3704 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Stolovich, M. et al. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell. Biol. 22, 8101–8113 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, T. A. et al. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science 266, 653–656 (1994).
  Article CAS PubMed Google Scholar
• Brunn, G. J. et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99–101 (1997).
  Article CAS PubMed Google Scholar
• Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H. & Sabatini, D. M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl Acad. Sci. USA 95, 1432–1437 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Gingras, A. C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N. & Hay, N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12, 502–513 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163–175 (2002).
  Article CAS PubMed Google Scholar
• Hara, K. et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177–189 (2002). References 114 and 115 report the identification of Raptor as a TOR-interacting protein necessary for the phosphorylation of TOR targets.
  Article CAS PubMed Google Scholar
• Nojima, H. et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278, 15461–15464 (2003).
  Article CAS PubMed Google Scholar
• Schalm, S. S., Fingar, D. C., Sabatini, D. M. & Blenis, J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13, 797–806 (2003).
  Article CAS PubMed Google Scholar
• Schalm, S. S. & Blenis, J. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12, 632–639 (2002).
  Article CAS PubMed Google Scholar
• Aoki, M., Blazek, E. & Vogt, P. K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl Acad. Sci. USA 98, 136–141. (2001).
  Article CAS PubMed Google Scholar
• Penuel, E. & Martin, G. S. Transformation by v-Src: Ras–MAPK and PI3K–mTOR mediate parallel pathways. Mol. Biol. Cell 10, 1693–1703 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Neshat, M. S. et al. Enhanced sensitivity of _PTEN_-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314–10319 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/− mice. Proc. Natl Acad. Sci. USA 98, 10320–10325 (2001). References 121 and 122 demonstrate that inhibition of TOR by the rapamycin derivative CCI-779 blocks tumour growth in a PTEN -deficient setting.
  Article CAS PubMed PubMed Central Google Scholar
• Minich, W. B. & Ovchinnikov, L. P. Role of cytoplasmic mRNP proteins in translation. Biochimie 74, 477–483 (1992).
  Article CAS PubMed Google Scholar
• Davydova, E. K., Evdokimova, V. M., Ovchinnikov, L. P. & Hershey, J. W. Overexpression in COS cells of p50, the major core protein associated with mRNA, results in translation inhibition. Nucleic Acids Res. 25, 2911–2916 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Evdokimova, V. M. & Ovchinnikov, L. P. Translational regulation by Y-box transcription factor: involvement of the major mRNA-associated protein, p50. Int. J. Biochem. Cell Biol. 31, 139–149 (1999).
  Article CAS PubMed Google Scholar
• Nekrasov, M. P. et al. The mRNA-binding protein YB-1 (p50) prevents association of the eukaryotic initiation factor eIF4G with mRNA and inhibits protein synthesis at the initiation stage. J. Biol. Chem. 278, 13936–13943 (2003).
  Article CAS PubMed Google Scholar
• Bader, A. G., Felts, K. A., Jiang, N., Chang, H. W. & Vogt, P. K. Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proc. Natl Acad. Sci. USA 100, 12384–12389 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Bader, A. G. & Vogt, P. K. Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol. Cell. Biol. 25, 2095–2106 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Preiss, T., Baron-Benhamou, J., Ansorge, W. & Hentze, M. W. Homodirectional changes in transcriptome composition and mRNA translation induced by rapamycin and heat shock. Nature Struct. Biol. 10, 1039–1047 (2003).
  Article CAS PubMed Google Scholar
• Grolleau, A. et al. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem. 277, 22175–22184 (2002).
  Article CAS PubMed Google Scholar
• Rajasekhar, V. K. et al. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 12, 889–901 (2003). Reports that existing mRNAs are differentially associated with polysomes in cells that have been transformed by AKT and SRC.
  Article CAS PubMed Google Scholar
• Graff, J. R. & Zimmer, S. G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Metastasis 20, 265–273 (2003).
  Article CAS PubMed Google Scholar
• Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231–241 (1997).
  Article CAS PubMed Google Scholar
• del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687–689 (1997).
  Article CAS PubMed Google Scholar
• Cardone, M. H. et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318–1321 (1998).
  Article CAS PubMed Google Scholar
• Fujita, N., Sato, S., Katayama, K. & Tsuruo, T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 277, 28706–28713 (2002).
  Article CAS PubMed Google Scholar
• Shin, I. et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nature Med. 8, 1145–1152 (2002).
  Article CAS PubMed Google Scholar
• Liang, J. et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Med. 8, 1153–1160 (2002).
  Article CAS PubMed Google Scholar
• Viglietto, G. et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nature Med. 8, 1136–1144 (2002).
  Article CAS PubMed Google Scholar
• Zhou, B. P. et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in _HER-2/neu_-overexpressing cells. Nature Cell Biol. 3, 245–252 (2001).
  Article CAS PubMed Google Scholar
• Kang, S., Bader, A. G. & Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl Acad. Sci. USA 102, 802–807 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Ikenoue, T. et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65, 4562–4567 (2005). References 141 and 142 report that high-frequency mutations in p110α that are associated with human tumours are oncogenic in cultured cells.
  Article CAS PubMed Google Scholar
• Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21, 99–102 (1999).
  Article CAS PubMed Google Scholar
• Byun, D. S. et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int. J. Cancer 104, 318–327 (2003).
  Article CAS PubMed Google Scholar
• Walker, E. H., Perisic, O., Ried, C., Stephens, L. & Williams, R. L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402, 313–320 (1999).
  Article CAS PubMed Google Scholar
• Kang, S., Bader, A. G., Zhao, L. & Vogt, P. K. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 4, 578–581 (2005).
  Article CAS PubMed Google Scholar
• Yu, J. et al. Regulation of the p85/p110 phosphatidylinositol 3′-kinase: stabilization and inhibition of the p110α catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 18, 1379–1387 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS PubMed Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
  Article CAS PubMed Google Scholar
• Pao, W. et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Tsao, M. S. et al. Erlotinib in lung cancer — molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133–144 (2005).
  Article CAS PubMed Google Scholar
• Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. Engl. 40, 2004–2021 (2001).
  Article CAS PubMed Google Scholar
• Manetsch, R. et al. In situ click chemistry: enzyme inhibitors made to their own specifications. J. Am. Chem. Soc. 126, 12809–12818 (2004).
  Article CAS PubMed Google Scholar
• Mocharla, V. P. et al. In situ click chemistry: enzyme-generated inhibitors of carbonic anhydrase II. Angew. Chem. Int. Ed. Engl. 44, 116–120 (2004).
  Article PubMed CAS Google Scholar
• Inoki, K., Li, Y., Xu, T. & Guan, K. L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829–1834 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C. & Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259–1268 (2003).
  Article CAS PubMed Google Scholar
• Saucedo, L. J. et al. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nature Cell Biol. 5, 566–571 (2003).
  Article CAS PubMed Google Scholar
• Garami, A. et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457–1466 (2003).
  Article CAS PubMed Google Scholar
• Zhang, Y. et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nature Cell Biol. 5, 578–581 (2003).
  Article CAS PubMed Google Scholar
• Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biol. 4, 648–657 (2002).
  Article CAS PubMed Google Scholar
• Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K. & Avruch, J. Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702–713 (2005).
  Article CAS PubMed Google Scholar
• Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G. L. & Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277, 27975–27981 (2002).
  Article CAS PubMed Google Scholar
• Hudson, C. C. et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004–7014 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Massion, P. P. et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am. J. Respir. Crit. Care Med. 170, 1088–1094 (2004).
  Article PubMed Google Scholar
• Pedrero, J. M. et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 114, 242–248 (2005).
  Article CAS PubMed Google Scholar
• Ma, Y. Y. et al. PIK3CA as an oncogene in cervical cancer. Oncogene 19, 2739–2744 (2000).
  Article CAS PubMed Google Scholar
• Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
  Article CAS Google Scholar
• Cheng, J. Q. et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 93, 3636–3641 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Balsara, B. R. et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25, 2053–2059 (2004).
  Article CAS PubMed Google Scholar
• Min, Y. H. et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17, 995–997 (2003).
  Article CAS PubMed Google Scholar